Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma

Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting m...

Descripción completa

Detalles Bibliográficos
Autores principales: Federico, Aniello, Steinfass, Tamara, Larribère, Lionel, Novak, Daniel, Morís, Francisco, Núñez, Luz-Elena, Umansky, Viktor, Utikal, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327877/
https://www.ncbi.nlm.nih.gov/pubmed/32637583
http://dx.doi.org/10.1016/j.omto.2020.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327877/
https://www.ncbi.nlm.nih.gov/pubmed/32637583
http://dx.doi.org/10.1016/j.omto.2020.06.001

Ejemplares similares